Does fenugreek cause gynaecomastia? This question is increasingly raised by men in the UK who take fenugreek supplements for testosterone support or athletic performance. Fenugreek contains steroidal saponins with theoretical oestrogenic properties, prompting concern about whether it could disturb hormonal balance and trigger breast tissue enlargement in males. This article examines the available clinical evidence, explains the mechanisms behind gynaecomastia, and provides clear guidance on when to seek medical advice — drawing on NHS, NICE, and MHRA frameworks to help you make an informed decision about fenugreek supplementation.

What Is Fenugreek and How Is It Used in the UK?

Fenugreek is an unregulated food supplement in the UK, available in capsules, powders, and teas, used for blood sugar support, galactagogue effects, and testosterone boosting, though none of these uses is endorsed by NHS or NICE guidelines.

Fenugreek (Trigonella foenum-graecum) is a plant native to the Mediterranean and South Asia, widely used both as a culinary spice and as a herbal supplement. In the UK, it is available over the counter in health food shops, pharmacies, and online retailers, typically in the form of capsules, powders, teas, or seed extracts. It is not a licensed medicine in the UK and is therefore regulated as a food supplement rather than a pharmaceutical product.

Fenugreek is commonly taken for a range of purposes, including:

• Supporting blood sugar regulation in people with type 2 diabetes

• Promoting milk production (galactagogue use) in breastfeeding women

• Boosting testosterone levels and supporting athletic performance

• Managing digestive complaints such as bloating and constipation

It is important to note that none of these uses is recommended by NHS or NICE guidelines, and the clinical evidence supporting them is limited and inconsistent. These should not be taken as endorsements of fenugreek for any medical purpose.

The seeds contain several bioactive compounds, including steroidal saponins (notably diosgenin), dietary fibre, and compounds sometimes described as having weak oestrogenic properties. Diosgenin is a steroidal sapogenin used in industrial pharmaceutical synthesis, but it is not converted to oestrogens or other steroid hormones in the human body. Any oestrogenic activity attributed to fenugreek in humans is theoretical and based largely on laboratory (in vitro) studies; its clinical relevance remains unestablished. It is this theoretical concern that has prompted questions about whether fenugreek could influence hormonal balance and, specifically, whether it might contribute to the development of gynaecomastia (enlargement of breast tissue in males).

Fenugreek supplements are not subject to the same rigorous pre-market safety and efficacy testing as licensed medicines. The Medicines and Healthcare products Regulatory Agency (MHRA) regulates herbal medicinal products under the Traditional Herbal Registration (THR) scheme or full marketing authorisation, but most fenugreek products are sold purely as food supplements and fall outside these schemes, being regulated only as foods under the Food Standards Agency (FSA). This means the quality, potency, and safety profile of individual products can vary considerably, and consumers cannot always be certain of what they are taking.

Fenugreek is a legume and cross-reactivity with other legumes such as peanuts and chickpeas has been reported. People with known legume allergies should exercise particular caution. Common side effects include gastrointestinal upset, a maple-syrup-like body odour, and, rarely, allergic reactions. Anyone experiencing allergic symptoms after taking fenugreek should stop use and seek medical advice promptly.

Understanding Gynaecomastia: Causes and Risk Factors

Gynaecomastia is benign male glandular breast enlargement caused by an elevated oestrogen-to-androgen ratio, with drug-induced causes accounting for an estimated 10–25% of all cases.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males, resulting from an imbalance between oestrogen and androgen (testosterone) activity at the level of breast tissue receptors. It is distinct from pseudogynaecomastia, which involves fatty tissue accumulation without true glandular proliferation. Gynaecomastia is relatively common, affecting up to 65% of adolescent males during puberty and a significant proportion of older men.

The underlying mechanism involves an increase in the oestrogen-to-androgen ratio at breast tissue receptors. This can arise through several pathways:

• Physiological causes: puberty, ageing, and neonatal hormonal shifts

• Pathological causes: hypogonadism, hyperthyroidism, liver cirrhosis, chronic kidney disease, and adrenal or testicular tumours

• Drug-induced causes: a well-recognised category including spironolactone, cimetidine, finasteride, dutasteride, anti-androgens, anabolic steroids, and some antipsychotics

• Substance use: cannabis, alcohol, and anabolic steroids are commonly implicated

Drug-induced gynaecomastia accounts for an estimated 10–25% of all cases and is an important consideration when evaluating any new or worsening breast tissue change in a male patient. Clinicians are advised to take a thorough medication and supplement history, as herbal and over-the-counter products are frequently overlooked.

According to NICE guidance (CKS: Gynaecomastia), a structured assessment should include a full drug history, physical examination, and targeted investigations such as liver function tests, renal function, thyroid function, and hormone levels (LH, FSH, testosterone, oestradiol, prolactin, and beta-hCG) to exclude underlying pathology. Testicular examination should be performed in all cases, and testicular ultrasound arranged if a testicular abnormality is suspected or if beta-hCG or oestradiol levels are raised. Breast imaging should be considered where there is clinical concern about a suspicious breast lesion. Identifying and removing the causative agent, where possible, is a key step in management.

Evidence Linking Fenugreek to Gynaecomastia

No robust clinical evidence links fenugreek supplementation to gynaecomastia in humans; available data are limited to isolated case reports and in vitro studies that do not reliably translate to clinical effects.

The question of whether fenugreek causes gynaecomastia has attracted interest, particularly among men using it as a testosterone-boosting supplement. The theoretical basis for concern relates to compounds in fenugreek that have demonstrated weak oestrogenic activity in laboratory settings. However, as noted above, diosgenin — the principal steroidal saponin in fenugreek — is not metabolised to oestrogens in the human body, and any clinically meaningful oestrogenic effect in humans has not been established.

There is currently no robust clinical evidence directly linking fenugreek supplementation to gynaecomastia in humans. No large-scale randomised controlled trials or epidemiological studies have established a causal relationship, and UK regulators have not identified a confirmed safety signal linking fenugreek to gynaecomastia. The available evidence consists primarily of:

• Isolated case reports and anecdotal accounts from online forums and supplement communities

• In vitro (laboratory) studies demonstrating oestrogenic activity of fenugreek extracts, which do not reliably translate to clinically meaningful effects in humans

• Small clinical trials examining fenugreek's effect on testosterone levels, with mixed and inconclusive results; many of these used proprietary extracts at specific doses and cannot be generalised

Some studies have suggested that certain fenugreek extracts may support free testosterone levels by inhibiting aromatase (the enzyme that converts testosterone to oestrogen) or 5-alpha reductase. These findings are hypothetical in the context of gynaecomastia risk, are based on limited human data, and should not be taken as confirmation that fenugreek is beneficial for testosterone or protective against gynaecomastia.

An important additional consideration for men using products marketed as 'testosterone boosters' is the risk of supplement adulteration or contamination. Some such products have been found to contain undeclared androgens, prohormones, or other hormonal substances that could themselves cause gynaecomastia. UK Anti-Doping (UKAD) advises caution with all sports supplements for this reason. If gynaecomastia develops in someone using a testosterone-boosting supplement, adulteration of the product should be considered as a possible cause alongside the labelled ingredients.

In summary, while theoretical concerns exist, there is no confirmed link between fenugreek use and gynaecomastia based on current clinical evidence. Absence of evidence does not exclude the possibility of idiosyncratic reactions in individual cases. Anyone who notices breast tissue changes whilst taking fenugreek or any supplement should not assume causation but should seek medical assessment to exclude other causes.

When to Seek Medical Advice About Breast Tissue Changes

Any male noticing breast swelling, tenderness, nipple discharge, or a hard lump should contact their GP promptly, as NICE NG12 recommends urgent two-week wait referral for men aged 50 or over with a unilateral firm subareolar mass.

Any male who notices changes in breast tissue — whether or not they are taking fenugreek or other supplements — should seek prompt medical evaluation. Whilst gynaecomastia is most commonly benign, it is essential to rule out serious underlying conditions, including testicular cancer, adrenal tumours, and other endocrine disorders.

You should contact your GP if you experience:

• Visible or palpable swelling or enlargement of one or both breasts

• Breast tenderness or pain (mastalgia)

• Nipple discharge of any kind

• A hard, irregular, or rapidly growing lump in the breast

• Breast changes accompanied by other symptoms such as unexplained weight loss, fatigue, or testicular changes

In line with NICE NG12 (Suspected cancer: recognition and referral), an urgent referral via the two-week wait (2WW) pathway should be considered for men aged 50 or over who present with a unilateral, firm subareolar mass with or without skin or nipple changes. An urgent referral should also be considered for any person with skin changes suggestive of breast cancer. For other presentations, your GP will assess whether an urgent or non-urgent referral is appropriate based on the full clinical picture. If a testicular abnormality is found or suspected, urgent urology referral and targeted imaging should be arranged.

When attending your GP, bring a full list of all medications, vitamins, and supplements you are taking — including herbal products such as fenugreek, protein powders, and testosterone boosters. This information is critical for accurate assessment. Your GP may arrange blood tests to assess hormone levels, liver and kidney function, and thyroid status.

Do not stop taking any prescribed medication without first speaking to your GP, even if you suspect it may be contributing to breast changes.

Safe Use of Herbal Supplements: MHRA and NHS Guidance

Most fenugreek products are sold as food supplements outside MHRA licensing, so consumers should look for the THR logo, report adverse reactions via the Yellow Card scheme, and inform their GP of all supplements taken, particularly if on warfarin or antidiabetic medicines.

Experiencing these side effects? Our pharmacists can help you navigate them →

In the UK, herbal supplements such as fenugreek sold as food supplements are not required to demonstrate safety or efficacy before being placed on the market. The MHRA regulates herbal medicinal products under the Traditional Herbal Registration (THR) scheme or full marketing authorisation; products bearing the THR logo have undergone a degree of quality assurance and safety review. However, most fenugreek products are sold as food supplements and fall outside these schemes, regulated only as foods under the Food Standards Agency (FSA). This regulatory gap means that consumers cannot always be certain of the purity, potency, or safety of herbal supplements.

The MHRA advises the public to:

• Look for the THR logo on herbal medicinal products, which indicates a degree of quality assurance and safety review

• Be cautious of products making medicinal claims without a licence, as these may be illegal and potentially unsafe

• Report suspected adverse reactions to herbal products via the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk/

• Inform all healthcare professionals of any supplements being taken, as interactions with prescribed medicines are possible

Fenugreek may potentially enhance the anticoagulant effect of warfarin, which could increase bleeding risk. This interaction has limited evidence in humans but is considered plausible given fenugreek's coumarin content. Anyone taking warfarin should discuss fenugreek use with their GP or anticoagulation clinic, and INR should be monitored closely if fenugreek is started or stopped. The Specialist Pharmacy Service (SPS) provides UK-based guidance on herbal medicine interactions for healthcare professionals.

Fenugreek may also have additive blood glucose-lowering effects when taken alongside antidiabetic medicines, potentially increasing the risk of hypoglycaemia. People with diabetes should discuss any supplement use with their diabetes team and monitor their blood glucose carefully.

Regarding breastfeeding: fenugreek is sometimes used as a galactagogue, but herbal galactagogues including fenugreek are not routinely recommended by UK services due to limited evidence of efficacy and uncertain safety. The SPS and NHS advise that breastfeeding support and addressing modifiable factors should be prioritised over herbal galactagogues.

Fenugreek is a legume, and cross-reactivity with peanuts, chickpeas, and other legumes has been reported. People with known legume allergies should avoid fenugreek supplements. If any allergic symptoms develop — such as rash, swelling, or breathing difficulty — stop use immediately and seek urgent medical attention.

Pregnant women, breastfeeding mothers, individuals with hormone-sensitive conditions, and those taking regular prescribed medication should seek advice from a GP or pharmacist before starting fenugreek or any herbal supplement. Whilst fenugreek is generally considered safe in culinary quantities, therapeutic doses in supplement form carry a different risk profile and should be approached with appropriate caution and professional guidance.

Frequently Asked Questions